Tejas Cargo IPO - Day 3 Subscription at 0.77 Times
Should You Consider Investing in Amwill Healthcare IPO?


Last Updated: 5th February 2025 - 10:43 am
Amwill Healthcare Limited is set to launch its Initial Public Offering (IPO), presenting a book-built issue aggregating to ₹59.98 crore.
The IPO combines a fresh issue of 44.04 lakh shares (₹48.88 crore) and an offer for sale of 10.00 lakh shares (₹11.10 crore) and opens for subscription on February 5, 2025, and closes on February 7, 2025. Allotments will be finalized by February 10, 2025, and listing is planned for February 12, 2025, on BSE SME.
i Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!
Established in August 2017, Amwill Healthcare has evolved into a specialized derma-cosmetic development company. The company operates through an asset-light model, collaborating with contract manufacturers, distributors, and third-party product development agencies.
Amwill Healthcare IPO is distinct because of the company’s comprehensive approach to dermatological solutions - from developing generic treatments to formulating targeted solutions for specific skin conditions. Their focus on conditions ranging from acne and fungal infections to anti-aging and vitiligo demonstrates their deep understanding of dermatological needs and market opportunities.
Why Invest in Amwill Healthcare IPO?
Understanding the investment potential of Amwill Healthcare requires examining several key aspects that make their business model particularly compelling:
- Specialized Focus - Their expertise in derma-cosmetic solutions creates a strong position in a growing healthcare segment.
- Strong Financial Growth - Revenue growth from ₹27.62 crore in FY22 to ₹36.05 crore in December 2023, along with significant profitability improvement, shows strong execution capabilities.
- Experienced Management - The promoter team of Anand Gandhi and Tarun Gandhi brings deep understanding of healthcare product development.
- Regional Strength - Strong presence in Karnataka, Andhra Pradesh, and Telangana provides stable market base for expansion.
- Asset-Light Model - Strategic partnerships with manufacturers and developers optimize capital efficiency.
Amwill Healthcare IPO: Key Dates to Know
Event | Date |
IPO Open Date | February 5, 2025 |
IPO Close Date | February 7, 2025 |
Basis of Allotment | February 10, 2025 |
Initiation of Refunds | February 11, 2025 |
Credit of Shares to Demat | February 11, 2025 |
Listing Date | February 12, 2025 |
Amwill Healthcare IPO Details
Details | Specifications |
Lot Size | 1,200 Shares |
IPO Size | ₹59.98 Cr |
IPO Price Band | ₹105-111 per share |
Minimum Investment | ₹1,33,200 |
Listing Exchange | BSE SME |
Financials of Amwill Healthcare Limited
Metrics | 31 Dec 2023 | FY23 | FY22 | FY21 |
Revenue (₹ Crore) | 36.05 | 30.28 | 27.62 | 18.00 |
Profit After Tax (₹ Crore) | 11.00 | 3.11 | 2.57 | -1.00 |
Assets (₹ Crore) | 20.14 | 12.39 | 6.59 | 8.29 |
Net Worth (₹ Crore) | 15.63 | 4.60 | 1.49 | -1.09 |
Reserves & Surplus (₹ Crore) | 15.58 | 4.57 | 1.46 | -1.12 |
Competitive Strengths and Advantages of Amwill Healthcare IPO
- Product Development - Their extensive portfolio and formulation capabilities ensure comprehensive market coverage.
- Strategic Partnerships - Collaborations with contract manufacturers and prototype developers enhance operational efficiency.
- Professional Team - With 59 employees including 31 in marketing, they have built strong development and distribution capabilities.
- Quality Focus - Partnerships with quality-focused manufacturers ensure product excellence.
- Market Understanding - Deep knowledge of dermatological needs drives product development.
Risks & Challenges of Amwill Healthcare IPO
- Regulatory Compliance - Healthcare product development requires adherence to strict quality and safety standards.
- Market Competition - Operating in the competitive derma-cosmetic sector requires continuous innovation.
- Geographic Concentration - Current focus on three states requires careful expansion management.
- Partner Dependencies - Reliance on contract manufacturers and third-party developers poses operational risks.
- Brand Development - Building brand recognition in new markets requires significant investment.
Amwill Healthcare IPO - Industry Landscape and Growth Potential
The Indian derma-cosmetic sector is experiencing remarkable transformation, driven by increasing awareness of skincare needs and growing disposable incomes. The sector's evolution is supported by technological advancement in formulations and changing consumer preferences.
The growth potential is supported by several key factors:
- Healthcare Awareness - Growing focus on skincare and dermatological treatments creates sustained demand.
- Market Expansion - Rising disposable incomes drive demand for quality skincare solutions.
- Distribution Development - Improving healthcare distribution networks enhance market reach.
- Innovation Focus - Advanced formulation technologies create opportunities for specialized products.
Conclusion - Should You Invest in the Amwill Healthcare IPO?
Amwill Healthcare Limited presents an attractive opportunity to invest in India's growing derma-cosmetic sector. The company's strong financial performance, with revenue growing from ₹18.00 crore in FY21 to ₹36.05 crore in December 2023, demonstrates excellent execution capabilities. Their specialized product portfolio and asset-light business model create sustainable competitive advantages.
The price band of ₹105-111 per share, with a P/E ratio of 15.13x (post-IPO), appears reasonable given the company's growth trajectory and sector potential. The planned utilization of IPO proceeds for working capital, marketing, and brand building indicates a focus on growth and market expansion. However, investors should consider the risks of regulatory compliance and geographic concentration.
The combination of strong financials, clear growth strategy, and positioning in a specialized healthcare segment makes Amwill Healthcare an interesting consideration for investors seeking exposure to India's dermatological solutions growth story.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Please consult a financial advisor before making investment decisions.
- Flat ₹20 Brokerage
- Next-gen Trading
- Advance Charting
- Actionable Ideas
Trending on 5paisa
02
5paisa Research Team
03
5paisa Research Team
IPOs Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.